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Abstract 
Although blood pressure (BP) control is crucial in hypertensive patients, clinical practice guidelines agree that the 
goal of treatment should be aimed at not only decreasing BP but reducing global cardiovascular risk. The aim of this 
cross-sectional study was to evaluate BP, low-density lipoprotein cholesterol (LDL-C), and composite control rates in 
a hypertensive population in a primary care setting in Spain. Good BP control was defined as <140/90 mm Hg 
(<130/80 mm Hg for diabetics).LDL-C control rate was established according to the third report of the National 
Cholestrol Education Program Adult Treatment Panel criteria. A total of 12,954 patients (49.9% women, aged 
62.1±10.7 years) were included. BP was controlled in 24.8% of patients, LDL-C in 26% of patients and, when 
combined, in only 8.6%. The rates of control were significantly worse in high-risk subgroups, such as high-coronary-
risk, diabetic, or metabolic syndrome patients. The BP and LDL-C control rates in the hypertensive population 
attended to daily in primary care settings in Spain are low. 
Hypertension is one of the main cardiovascular (CV) risk factors. Different guidelines have shown 
that the presence of hypertension increases CV morbidity and mortality. The Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 
7)1 and the European guidelines for the management of arterial hypertension2 show that even small 
elevations above optimal blood pressure (BP) values increase the likelihood of developing a CV disease. 
In 1990, MacMahon and colleagues3 demonstrated that BP lowering is critical in reducing the risk of CV 
outcomes and preventing major coronary events. Nevertheless, although BP control is crucial, clinical 
practice guidelines agree that the aim of treatment in hypertensive patients should not only be to control 
BP but to reduce CV risk. Thus, a multifactorial intervention appears to be critical in improving CV 
prognosis in hypertensive patients.2 
In the United States, the third report of the National Cholesterol Education Program Adult Treatment 
Panel (NCEP ATP III)4 establishes low-density lipoprotein cholesterol (LDL-C) level control as a main 
objective for the primary and secondary prevention of coronary disease. It is well known that the 
prevalence of hypercholesterolemia is higher in the hypertensive population and vice versa5,6 Treatment 
of multiple risk factors may improve CV risk in hypertensive patients. Clinical trials, such as the Anglo-
Scandanavian Cardiac Outcomes Trial (ASCOT),7–9 have demonstrated that the integration of a 
multifactorial approach reduces the risk of CV morbidity and mortality. 
Nevertheless, epidemiologic studies often analyze different CV risk factors independently. The 
Prevención Cardiovascular en España en Atención Primaria: Intervención Sobre el Colesterol en 
Hipertensión (PRESCOT) study is a cross-sectional trial designed to determine not only the BP control 
but also the LDL-C and the composite of BP and LDL-C control rates in the hypertensive population 
treated in a primary care setting. In addition, the BP, LDL-C level, and the composite control rates in 
high-risk patient subgroups, such as patients with high coronary risk, diabetes, or the metabolic syndrome 
(MetS), are determined. 
Preliminary data of this study were presented at the 20th Annual Scientific Meeting of the American 
Society of Hypertension in San Francisco, CA, May 14–18, 2005. 
  
Patients and methods 
Study Population 
The study population involved patients with hypertension included in the PRESCOT cross-sectional 
epidemiologic survey. The study was aimed to determine the BP, LDL-C, and composite control rates in a 
population of patients with hypertension attending general practice clinics across Spain daily. 
Approximately 2000 primary care physicians participated in the study, which was performed during 2004. 
Each investigator was asked to include the first 6 consecutive outpatients with hypertension who were 
seen at the clinic. Men and women older than 18 years who had an established diagnosis of hypertension 
and an available blood test with a complete lipid profile performed within the past 6 months were 
included in the study. To correctly reflect the clinical daily practice, no specific exclusion criteria were 
defined. 
Methodology and Data Collection 
BP readings were taken with mercury sphygmomanometers or validated automatic devices where 
available, after 5 minutes of rest. The patient was in a seated position with the back supported. Two 
measurements were taken, and the mean was recorded. BP was considered to be well controlled according 
to the 2003 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guideline 
recommendations (<140/90 mm Hg for the general population and <130/80 mm Hg for diabetic 
patients).2 Patients were classified as being at low, medium, or high coronary risk according to the NCEP 
ATP III classification.4 We used NCEP ATP III guidelines because of their utility in identifying coronary 
risk in clinical practice and their definition of LDL-C goals. LDL-C control was thus defined in relation 
to the above risk categories: LDL-C <100 mg/dL for the high-risk group, <130 mg/dL for the medium-
risk group, and <160 mg/dL for the low-risk group.4 
MetS was diagnosed using NCEP ATP III criteria requiring the presence of 3 or more of the following 
factors: abdominal obesity (waist circumference >102/88 cm or >40/35 inches for men/women); 
triglyceride level ≥150 mg/dL; high-density lipoprotein cholesterol level <40/50 mg/dL (men/women); 
fasting glucose level ≥110 mg/dL; or BP ≥130/85 mm Hg.4 Waist circumference was measured at the 
midpoint between the iliac crest and the costal margin. Smoking was defined as current smokers of ≥1 
cigarette per day and exsmokers who had stopped smoking for more than 12 months. Excessive alcohol 
intake was classified as a weekly consumption of the equivalent of 26 oz of 40-proof alcohol. Sedentary 
lifestyle was defined as the physical activity undergone in a period shorter than a 30-minute daily walk, 
and renal failure by a serum creatinine level >1.5 mg/dL in men and >1.4 mg/dL in women, according to 
European guidelines.2 The presence of diabetes was recorded from the clinical history. The diagnosis of 
left ventricular hypertrophy was reported by the investigator either by electrocardiography or 
echocardiography. The physicians fulfilled a specific individual case report form with all of the collected 
clinical and analytic data for every patient. 
Statistical analyses 
Various statistical tests were performed depending on the nature of the variables being compared. The 
chi-square test was used to analyze the relationship between categoric variables. When more than 20% of 
the cells had an expected frequency of lower than 5, however, the Fisher exact test was used. Comparison 
of continuous variables between groups was performed using the Student t-test. Database recording was 
subjected to internal consistency rules and ranges to control inconsistencies/inaccuracies in the collection 
and tabulation of data (SPSS version 11.0.1; SPSS Inc, Chicago, IL). 
Results 
The PRESCOT survey enrolled a total of 15,707 patients of whom 12,954 (82.5%) were included in 
the analysis after excluding those who did not comply with the selection criteria and/or whose case report 
forms were incomplete and/or inconsistent. Table I details the baseline characteristics of the overall study 
population. Mean age was 62.1±10.7 years and 49.9% were women. Body mass index was 28.5±4.1 
kg/m2 and waist circumference was 99.3±16.0 cm (101.8±14.3 cm in men and 96.9±17.1 in women). 
Mean BP values were 144.1±14.2/85±9.1 mm Hg. The time of evolution of hypertension was 6.7±5.4 
years. A total of 76% of the patients had dyslipidaemia, 52% had MetS, and 29.9% had diabetes. The 
most frequent target organ damage was left ventricular hypertrophy (11.9%) and the most frequent 
associated clinical condition was coronary artery disease (13.6%). 
Table I.  Characteristics of the PRESCOT Study Population (N=12,954) 
 
Demographic data 
Women 6468 (49.9) 
 Age, y 62.1±10.7 
Body mass index, kg/m2 Men: 28.4±3.6 
Women: 28.5±4.6 
Waist circumference, cm Men: 101.8±14.3 
Women: 96.9±17.1 
Cardiovascular risk factors 
 Dyslipidemia 9850 (76.0) 
 Diabetes 3868 (29.9) 
 Smoking 4875 (37.6) 
 Family history of premature coronary disease 4209 (32.5) 
Vascular disease 
 Heart disease 4164 (32.1) 
 Left ventricular hypertrophy 1539 (11.9) 
 Coronary disease 1765 (13.6) 
 Heart failure 591 (4.6) 
 Renal impairment 1358 (10.5) 
 Microalbuminuria 851 (6.6) 
 Proteinuria 143 (1.1) 
 Renal failure, serum creatinine* 351 (2.7) 
 Stroke 699 (5.4) 
 Peripheral arterial disease 566 (4.4) 
Clinical data 
 SBP, mm Hg 144.1±14.2 
 DBP, mm Hg 85.0±9.1 
Biochemical data 
 Total cholesterol, mg/dL 233.1±41.8 
 Triglycerides, mg/dL 158.1±80.0 
 LDL cholesterol, mg/dL 150.9±92.8 
 HDL cholesterol, mg/dL 53.3±18.1 
 Fasting plasma glucose, mg/dL 110.5±32.0 
 Uric acid, mg/dL 5.4±1.9 
 
Values are mean ± SD or No. (%). *For men, serum creatinine values >1.5 mg/dL and for women, 1.4 mg/dL. PRESCOT indicates 
Prevención Cardiovascular en España en Atención Primaria: Intervención Sobre el Colesterol en Hipertensión; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; and HDL, high-density lipoprotein. 
Most patients (94.5%) were taking at least 1 drug, but 5.5% of patients were not receiving 
pharmacologic treatment. More than half (55.9%) of the patients with antihypertensive medication were 
on monotherapy, and 38.6% were treated with 2 or more drugs. The most frequently prescribed 
antihypertensive agents were the angiotensin-converting enzyme inhibitors and the more common 
combination was a diuretic with an inhibitor of the renin-angiotensin system. Despite 76% of the patients 
being dyslipidemic, only 41% were treated with lipid-lowering agents, with statins being the most 
frequently prescribed. 
BP was controlled in 24.8% of patients. Systolic BP was controlled in 28.5% of patients, while 
diastolic BP was controlled in 50.9%. The LDL-C control rate was 26%. The degree of control of 
combined BP and LDL-C was very low (8.6%). Overall study population BP and LDL-C control data are 
presented in the Figure. Predictive factors of uncontrolled BP were diabetes, renal impairment, excessive 
alcohol intake, sedentary lifestyle, and left ventricular hypertrophy (P<.05), and those for lack of LDL-C 
control were diabetes, the presence of associated clinical conditions, uncontrolled BP, excessive alcohol 
intake, overweight, sedentary lifestyle, and absence of lipid-lowering treatment (P<.05). Table II and 
Table III show the odds ratios and confidence intervals of the predictive factors for uncontrolled BP or 
LDL-C. 
Table II.  Predictive Factors for Lack of BP Control (P<.05) 
Predictive Factors Odds Ratio 95% Confidence Interval 
   
Diabetes 6.37 5.51–7.37 
Renal impairment 2.77 2.16–3.55 
Excessive alcohol intake 1.41 1.27–1.56 
Sedentary lifestyle 1.35 1.23–1.47 
Left ventricular hypertrophy 1.23 1.06–1.42 
   
 
Table III.  Predictive Factors for Lack of Low-Density Lipoprotein Cholesterol Control (P<.05) 
Predictive Factors Odds Ratio 95% Confidence Interval 
   
Diabetes 3.13 2.77–3.55 
Associated clinical conditions* 1.74 1.56–1.95 
No blood pressure control 1.54 1.40–1.71 
Excessive alcohol intake 1.35 1.19–1.52 
Overweight (25–30 kg/m2) 1.21 1.08–1.37 
Sedentary lifestyle 1.16 1.05–1.27 
Lipid-lowering agents treatment 0.79 0.72–0.87 
 
*Includes stroke, peripheral arterial disease, coronary disease, and heart failure. 
The control rates in high-risk subgroups (patients with high coronary risk, diabetes, or MetS) were 
lower than the comparators (for all, P<.0001) (Figure). BP was well controlled in 37.5% of the low-risk 
subgroup, in 30.2% of the medium-risk group, and in 15.4% of the high-risk subgroup.LDL-C control 
was 65.6% in the low-risk group, 28% in the medium-risk group, and 12.3% in the high-risk group. Only 
25.8% of the patients at low risk had both controlled BP and LDL-C, whereas 9.6% of medium-risk 
patients and 2.7% of high-risk group had controlled BP and LDL-C. 
  
 
 
 
Blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), and combined control rates according to coronary risk and the 
presence of diabetes mellitus (DM) and the metabolic syndrome (MetS). 
BP was controlled in fewer patients in the subgroup of MetS compared with those without MetS 
(17.2% vs 33.6%; P<.0001). Systolic BP was controlled in 20.7% of MetS patients and in 37.2%of non-
MetS patients (P<.0001), while diastolic BP was controlled in 39.0% vs 63.7% (P<.0001), respectively. 
Similarly, LDL-C control was worse in MetS patients than in patients without MetS (17.2% vs 35.7%; 
P<.0001). The combined control of both risk factors was also lower in patients with the MetS (4.7% vs 
13.5%; P<.0001). 
In diabetics, BP control (<130/80 mm Hg) and LDL-C control (<100 mg/dL) were lower than in 
patients without diabetes (6.3% vs 32.7% [P<.001] and 12% vs 31.9% [P<.001]). In only 1.0% of the 
patients with diabetes, both parameters were properly controlled (vs 11.9% of patients without diabetes; 
P<.001). When considering BP control <140/90 mm Hg, 22.9% of diabetics vs 32.7% of nondiabetics 
attained goal (P<.001). 
Discussion 
In the past few years, a number of pivotal studies on the early detection and BP control treatment of 
hypertension have been performed. These studies have shown a progressive improvement in the rates of 
BP control lately.10–12 Nevertheless, surveys reveal that in more than 50% of patients treated for 
hypertension, it is not yet controlled.13,14 As evidence shows, the aim of treatment in hypertensive patients 
should not only be to control BP values but mainly to reduce CV risk.2 Although recent guidelines 
emphasize the concomitant management of multiple CV risk factors, few studies have assessed treatment 
patterns and combined BP and LDL-C goal attainment in the hypertensive population.15–17 Our results 
show that BP and LDL-C control rates are globally low but are even worse in high-risk patients, such as 
patients with diabetes or MetS, or those classified as being at high coronary risk according to NCEP ATP 
III guidelines. Several studies have shown similar results.5,15–20 Despite the fact that the Mediterranean 
population seems to exhibit a low CV risk when compared with those in other Western countries,21 most 
patients who are treated in primary care clinics in Spain are actually at medium or high coronary risk.5,20 
Therefore, it is critical to identify the associated risk factors and to take a global multifactorial therapeutic 
approach to improve the prognosis of hypertensive patients. 
Regarding BP control rates, our data show that only 24.8% of patients achieve BP goals. Several 
studies have shown poor BP control in the primary care setting.10–12,22 Our data are consistent with these 
studies; however, this situation does not only occur in primary care but also in hospital hypertension 
units, as the CLUE study23 demonstrated. A number of factors may be involved in this lack of BP control 
in clinical practice, including the underestimation of real risk, the scarce importance given to systolic BP, 
poor treatment adherence, and therapeutic inertia.5,10,24,25 Clinical inertia implies that physicians do not 
usually make changes even though BP is not controlled.26 Our study shows that despite the fact that 
primary care hypertensive patients who attend an outpatient clinic daily present a high coronary risk, only 
56% of them are taking antihypertensive monotherapy. This low proportion of combined therapy may 
play a role in the low BP control rates. Moreover, in high-risk patients it is more difficult to achieve BP 
goals. As an example, while BP control is considered to be <140/90 mm Hg in diabetics, the control rates 
were higher in nondiabetics. 
Several studies have been aimed at determining lipid control. These studies showed very low LDL-C 
control rates in high-coronary-risk patients in primary care.27–29 In the same way, poor goal attainment 
was observed in the Lipid Treatment Assessment Project (L-TAP),30 in which only 40% of dyslipidemic 
patients receiving statin monotherapy reached their LDL-C goals. Moreover, this situation does not 
improve in hospitalized patients.31,32 Our results are consistent with these data. Despite that 76% of the 
study population had dyslipidemia and that LDL-C control rates were low, only 41% were treated with 
lipid-lowering agents. This situation is even worse in patients with diabetes, MetS, or high coronary risk. 
Our results showed that diabetes was the main predictor of the lack of BP and LDL-C control. Of 
interest, the absence of BP control is a predictive factor of no LDL-C control, which emphasizes the 
relationship between BP and hypercholesterolemia and the importance of globally treating the patient.6 In 
the hypertensive population, it is critical to control not only BP but other CV risk factors as well. A recent 
study showed that less than half of all treated patients reach the therapeutic goal for either BP or LDL-
C.16 Researchers observed that very few patients with concomitant hypertension and dyslipidemia, 
especially among those patients with diabetes, attained their therapeutic goals for both BP and LDL-C. 
Similarly, our data showed that in high-risk patients, both parameters are often poorly controlled, which 
may imply relevant clinical consequences. The ASCOT trial is a clear example of how the treatment of 
associated CV risk factors in hypertension results in a significant improvement of prognosis.9 Therefore, 
patients with hypertension need to be treated with more antihypertensive combined therapy and statins. 
Antihypertensive treatment and lipid-lowering agents, however, are not the only important agents that 
should be used in the treatment of hypertensives. Our results show that despite that nearly one third of the 
overall population had heart disease, fewer than a quarter of patients received antiplatelet therapy. 
Therefore, a global approach is warranted to improve CV prognosis in hypertensive patients and even 
more in high-risk subgroups. 
The cross-sectional design of the study was chosen to represent the “real world” of clinical practice as 
best as possible. Consequently, a large population of hypertensive patients was included in the trial by 
consecutive sampling. This methodology has limitations because it reduces the level of control that can be 
exercised to reduce variation and bias (eg, random sampling and blind controls). The large number of 
patients included and the nature of the end points being measured, however, with no comparators under 
review, minimizes this theoretic limitation. In fact, the study was designed to represent clinical practice, 
presenting an accurate picture of the hypertensive population who were managed daily in primary care. 
In conclusion, the PRESCOT study is one of the very few studies performed in the primary care 
setting that analyzed both BP and LDL-C control rates in hypertensive patients. This study includes a 
large sample of patients who were seen daily by general practitioners and demonstrates that BP and LDL-
C control rates are low and that there are few patients who have both risk factors adequately controlled. 
Notably, fewer than 9% of hypertensive patients have both parameters well controlled, and this is even 
worse in high-risk patients, which may result in significant clinical implications. This management of 
hypertensive patients through an aggressive multifactorial approach for reducing the CV risk in general 
practice requires improvement. 
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